Welcome to our dedicated page for AUTOLUS THERAPEUTICS PLC news (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on AUTOLUS THERAPEUTICS PLC stock.
Autolus Therapeutics plc (Nasdaq: AUTL) generates frequent news as an early commercial-stage biopharmaceutical company focused on next-generation programmed T cell therapies for cancer and autoimmune disease. News coverage for AUTL often centers on AUCATZYL® (obecabtagene autoleucel; obe-cel), the company’s CD19-directed CAR T cell therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and on the clinical and commercial progress of this product.
Investors and healthcare observers following Autolus news will see updates on AUCATZYL net product revenue, treatment center activation, and reimbursement developments such as NICE recommendations and conditional marketing authorizations in the UK and EU. Press releases also describe real-world data from consortia like ROCCA, which evaluate safety and response rates for AUCATZYL in clinical practice, alongside analyses from the FELIX study that explore CAR T-cell persistence and product cell phenotypes as potential predictors of long-term outcomes.
Autolus regularly reports clinical data from its broader pipeline, including the CATULUS trial in pediatric relapsed or refractory B-ALL, the CARLYSLE Phase 1 study in severe refractory systemic lupus erythematosus, the LUMINA Phase 2 trial in lupus nephritis and the BOBCAT trial in progressive multiple sclerosis. These updates typically highlight remission rates, safety profiles, B-cell depletion and immune reset signals in autoimmune indications. Additional news items cover collaborations, such as the evaluation of Cellares’ automated Cell Shuttle platform to support high-throughput CAR T manufacturing, and corporate developments including leadership appointments and participation in healthcare conferences.
This news page allows readers to track Autolus’ ongoing clinical milestones, regulatory and reimbursement decisions, manufacturing initiatives and financial disclosures related to its T cell therapy programs. For those monitoring AUTL, the flow of updates provides context on how AUCATZYL and pipeline candidates are progressing across hematologic malignancies, solid tumors and autoimmune diseases.
Autolus Therapeutics plc (Nasdaq: AUTL) announced its operational and financial results for Q4 and FY 2020, showcasing a robust financial position after raising $131 million, enabling a cash runway into H1 2023. The company's AUTO1 program for adult B-ALL has shown promising results, with an 84% MRD-negative response in treated patients. However, net loss rose to $142.1 million in 2020, compared to $123.8 million in 2019. Management expects multiple clinical readouts in 2021 and 2022, including updates on AUTO1 and other CAR T therapies.
Autolus Therapeutics plc (Nasdaq: AUTL) announced that CEO Dr. Christian Itin will present at the virtual H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The event will feature one-on-one meetings with participants. A live audio webcast of the presentation will be available on Autolus’ investor relations page starting March 9 at 7:00 a.m. EST, with an archived replay accessible for 90 days. Autolus is focused on developing next-generation programmed T cell therapies aimed at treating various cancers.
Autolus Therapeutics plc (Nasdaq: AUTL) has successfully closed a public offering of 16,428,572 ADSs at a price of $7.00 each, raising approximately $115 million in gross proceeds. The offering included the full exercise of an option by underwriters for an additional 2,142,857 ADSs. J.P. Morgan and Wells Fargo Securities were the joint bookrunners for this transaction. The funds will support the development of Autolus' next-generation T cell therapies aimed at treating cancer, leveraging advanced programming technologies to improve efficacy against malignancies.
Autolus Therapeutics plc (Nasdaq: AUTL) has priced a public offering of 14,285,715 American Depositary Shares (ADSs) at $7.00 each, aiming to raise approximately $100 million. The offering is expected to close on February 12, 2021, pending customary conditions. Additionally, underwriters have a 30-day option to purchase up to 2,142,857 ADSs.
This offering follows an effective shelf registration statement with the SEC, and all securities will be offered solely through a prospectus. Autolus is focused on developing advanced T cell therapies for cancer treatment.
Autolus Therapeutics plc (Nasdaq: AUTL) has announced a public offering of up to $100 million of its American Depositary Shares (ADSs). The offering, managed by J.P. Morgan and Wells Fargo Securities, may include an additional $15 million option for underwriters. This move is part of the company's strategy to support its development of next-generation T cell therapies for cancer. The offering is subject to market conditions, with no assurance regarding completion or terms.
Autolus Therapeutics (Nasdaq: AUTL) will disclose its Q4 2020 and full-year financial results on March 4, 2021, prior to U.S. market open. The company develops next-generation programmed T cell therapies and is expected to provide operational highlights during this release. A conference call will occur at 8:30 am ET, featuring a general business update and an opportunity for investors to engage. For those interested, access to the call will be available via the company’s website and dedicated phone lines.
Autolus Therapeutics plc (Nasdaq: AUTL) is prioritizing its CAR T cell therapy, AUTO1, targeting Adult Acute Lymphoblastic Leukemia (ALL). Key data from the AUTO1-AL1 study is expected in 2022. The company aims to partner its AUTO3 program and adjust its workforce by approximately 20%, anticipating annual cash savings of about $15 million. AUTO1 demonstrated promising results with a 52% event-free survival at 12 months. Autolus is advancing its pipeline focused on oncology, aiming for pivotal data and exploring additional B-cell malignancies.
Autolus Therapeutics plc (Nasdaq: AUTL) announced participation in investor conferences in January 2021. Key events include:
- 11 January 2021 - Presentation at the H.C. Wainwright BioConnect 2021 Conference available on demand from 6:00 am ET.
- 13 January 2021 - Presentation at the 39th Annual J.P. Morgan Healthcare Conference at 9:10 am ET, with virtual meetings and a live webcast.
Archived replays will be accessible for 30 days post-conferences. Autolus develops innovative T cell therapies for cancer treatment.
Autolus Therapeutics (AUTL) announced progress on its CAR T product candidate AUTO3 at the ASH Annual Meeting. The ALEXANDER study, focusing on relapsed/refractory diffuse large B cell lymphoma, showed AUTO3 to be well tolerated, with low rates of cytokine release syndrome and neurotoxicity. The overall objective response rate was 65%, with a complete response rate of 51%. Notably, higher dosing improved outcomes, with an 87% response rate at the highest dose. The company is evaluating a strategy to optimize AUTO3's development path and will provide updates in Q1 2021.
Autolus Therapeutics announced promising results from its AUTO1 CAR T cell therapy in the ongoing ALLCAR Phase 1 study for adult patients with relapsed/refractory B-Acute Lymphocytic Leukemia (ALL). As of November 12, 2020, 20 patients had received AUTO1, showing a tolerance profile with no Grade 3 cytokine release syndrome. Among evaluable patients, 84% achieved minimal residual disease-negative complete response at one month, with encouraging overall survival rates. The pivotal Phase 1b/2 study is anticipated to enroll patients throughout 2021, with full data expected in 2022.
FAQ
What is the current stock price of AUTOLUS THERAPEUTICS PLC (AUTL)?
What is the market cap of AUTOLUS THERAPEUTICS PLC (AUTL)?
